专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017218638A1 METHODS FOR TREATING SUBJECTS SUFFERING FROM ACUTE MYELOID LEUKEMIA WITH FLT3 LIGAND-TARGETED MIR-150 NANOPARTICLES 审中-公开
标题翻译：用FLT3配体靶向的MIR-150纳米颗粒治疗患有急性髓细胞性白血病的受试者的方法
公开(公告)号：WO2017218638A1
公开(公告)日：2017-12-21
申请号：PCT/US2017/037424
申请日：2017-06-14
申请人： CHEN, Jianjun , HONG, Seungpyo , JIANG, Xi , LI, Zejuan
发明人： CHEN, Jianjun , HONG, Seungpyo , JIANG, Xi , LI, Zejuan
IPC分类号： A61K31/7088 , A61K38/17 , A61K38/19 , A61K38/20 , A61K39/00
CPC分类号： A61K47/6935 , A61K31/551 , A61K31/7105 , A61K38/19 , A61K45/06 , A61K47/595 , A61K47/62 , A61P35/02 , C12N15/1138 , C12N2310/141 , C12N2310/321 , A61K2300/00
摘要： A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3 -overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.
摘要翻译：设计用于持续递送microRNA-150（miR-150）至FLT3-过表达急性骨髓性白血病（AML）细胞的纳米粒子递送系统，所述递送系统包含聚（（PAMAM）树枝状化合物与miR-150复合，其中至少一个树枝状聚合物用FLT3受体特异性配体表面官能化，并提供了治疗特征在于FLT3过表达的AML的方法。 / p>

2. 发明申请

WO2007113507A1 POWER SUPPLY SYSTEM 审中-公开
标题翻译：电源系统
公开(公告)号：WO2007113507A1
公开(公告)日：2007-10-11
申请号：PCT/GB2007/001165
申请日：2007-03-30
申请人： THE UNIVERSITY OF SUSSEX , UNIVERSITY OF BRIGHTON , UNIVERSITY COLLEGE LONDON , IMPERIAL COLLEGE OF SCIENCE , BRUNEL UNIVERSITY , STOBART, Richard, Keith , PENG, Zhijun , CHAUDHARI, Anita, Raghunath , HEIKAL, Morgan, Raymond , MONAGHAN, Michael, Louis , LADOMMATOS, Nicos , HARDALUPAS, Ioannis , TAYLOR, Alexander, Marinos, Kriton, Peter , ZHAO, Hua , JIANG, Xi , MA, Thomas, Tsoi-Hei
发明人： STOBART, Richard, Keith , PENG, Zhijun , CHAUDHARI, Anita, Raghunath , HEIKAL, Morgan, Raymond , MONAGHAN, Michael, Louis , LADOMMATOS, Nicos , HARDALUPAS, Ioannis , TAYLOR, Alexander, Marinos, Kriton, Peter , ZHAO, Hua , JIANG, Xi , MA, Thomas, Tsoi-Hei
IPC分类号： H01M8/04 , H01M8/06 , H01M8/00 , B60L11/00
CPC分类号： H01M8/04 , B60L11/1881 , H01M8/00 , H01M8/04455 , H01M8/04805 , H01M8/04925 , H01M8/0662 , H01M2250/20 , H01M2250/407 , Y02E60/563 , Y02T90/32 , Y02T90/34
摘要： A power supply system comprises an internal combustion engine (1) and a fuel cell (2) arranged in series with each other, together with an appropriate fuel supply (6) and an air supply (3) for the fuel cell (2) and internal combustion engine (1). The stream of fuel gas (7) which is exhausted from the anode of the fuel cell (2) is provided as a fuel supply input to the fuel supply system of the internal combustion engine (1). The fuel cell (2) is controlled so as to control the composition of exhausted fuel supply stream (7) that is input from it into the internal combustion engine (1). This is achieved by controlling the fuel cell (2) to remove (consume) a desired amount of the combustible. material (fuel) in the fuel supplied to it, before that fuel is supplied to the internal combustion engine.
摘要翻译：电源系统包括内燃机（1）和与燃料电池（2）的合适燃料供应（6）和空气供应（3）相互串联布置的燃料电池（2）和内燃机（1）。从燃料电池（2）的阳极排出的燃料气体（7）设置为作为内燃机（1）的燃料供给系统的燃料供给输入。控制燃料电池（2）以控制从其输入到内燃机（1）中的排出的燃料供给流（7）的组成。这是通过控制燃料电池（2）去除（消耗）所需量的可燃物来实现的。燃料供应给内燃机之前的燃料中的材料（燃料）。

3. 发明申请

WO2010144602A2 ANTIGEN-NOROVIRUS P-DOMAIN MONOMERS AND DIMERS, ANTIGEN-NOROVIRUS P-PARTICLE MOLECULES, AND METHODS FOR THEIR MAKING AND USE 审中-公开
标题翻译：抗逆转录病毒单核细胞和二聚体，抗逆转录病毒颗粒分子及其制备和使用方法
公开(公告)号：WO2010144602A2
公开(公告)日：2010-12-16
申请号：PCT/US2010/038008
申请日：2010-06-09
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER , JIANG, Xi , TAN, Ming
发明人： JIANG, Xi , TAN, Ming
IPC分类号： C07K19/00 , C12N15/63 , A61K39/295 , A61P37/00
CPC分类号： C07K7/06 , A61K38/00 , A61K39/12 , A61K39/125 , A61K2039/5258 , A61K2039/542 , A61K2039/543 , A61K2039/55566 , A61K2039/58 , A61K2039/6075 , A61K2039/645 , A61K2039/70 , C07K5/10 , C12N2720/12334 , C12N2770/16034
摘要： A substituted Norovirus capsid protein monomer, having only the P-domain and called an antigen-Norovirus P-domain monomer, includes a foreign antigen inserted into one or more of three surface loops present on each P-domain monomer by molecular cloning. The antigen-P-domain monomer can assemble spontaneously into an octahedral form, called an antigen-Norovirus P-particle, that is composed of 24 copies of the antigen-P-domain monomer. Each substituted P-domain monomer will contain one to three copies of the foreign antigen, for a total of 24-72 antigen copies on each antigen-P-particle. The antigen-P-particle is useful in methods for diagnosing, immunizing and treating individuals infected with a foreign virus, for example Rotavirus, and can serve as a carrier for presentation of foreign antigens for development of novel vaccines against many infectious and non-infectious diseases. The substituted Norovirus P-particles can be readily produced in E. coli and yeast, are highly stable and tolerate a wide range of physio-chemical conditions. A modified Norovirus P-domain monomer includes one or more restriction recognition sites inserted within one or more of the three loops of the P-domain monomers, to provide user-friendly cloning cassettes for conveniently inserting candidate foreign antigens into the surface loops. The P-particle-VP8 chimeras may also serve as a dual vaccine against both rotavirus and norovirus.
摘要翻译：仅具有P-结构域并称为抗原 - 诺如病毒P-结构域单体的取代的诺如病毒衣壳蛋白单体包括通过分子克隆插入每个P-结构域单体上存在的三个表面环中的一个或多个的外源抗原。抗原-P结构域单体可以自发组装成称为抗原 - 诺如病毒P颗粒的八面体形式，其由24个抗原-P结构域单体组成。每个取代的P-结构域单体将含有一至三个拷贝的外源抗原，每个抗原-P-粒子上共有24-72个抗原拷贝。抗原-P颗粒可用于诊断，免疫和治疗感染外来病毒的个体的方法，例如轮状病毒（Rotavirus），并且可以用作外源抗原的载体，用于开发针对许多感染性和非感染性的新型疫苗疾病。取代的诺如病毒P颗粒可以容易地在大肠杆菌和酵母中产生，高度稳定并且耐受广泛的生理化学条件。修饰的诺如病毒P结构域单体包括插入在P结构域单体的三个环中的一个或多个环内的一个或多个限制性识别位点，以提供方便地将候选外源抗原插入到表面环中的用户友好的克隆盒。 P粒子VP8嵌合体也可以用作针对轮状病毒和诺如病毒的双重疫苗。

4. 发明申请

WO2006138514A2 NOVEL NOROVIRUS PARTICLE FOR USE AS AN ANTIVIRAL OR VACCINE 审中-公开
标题翻译：用作抗病毒剂或疫苗的新型尿毒症颗粒
公开(公告)号：WO2006138514A2
公开(公告)日：2006-12-28
申请号：PCT/US2006/023407
申请日：2006-06-15
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER , JIANG, Xi , TAN, Ming
发明人： JIANG, Xi , TAN, Ming
IPC分类号： A61K39/12
CPC分类号： G01N33/56983 , A61K39/00 , A61K2039/5258 , C07K14/005 , C12N2770/16022 , C12N2770/16023 , Y02A50/472 , Y02A50/52
摘要： Norovirus capsid protein monomers having only the P domain, and not the hinge or S domain, can assemble spontaneously into an icosahedral form herein called the P-particle. Factors affecting the formation and stability of the P-particle, as well as providing methods for diagnosing and treating Norovirus-infected individuals and creating a vaccine for prevention of Norovirus infection are presented.
摘要翻译：仅具有P结构域而不是铰链或S结构域的诺如病毒衣壳蛋白单体可以自发地组装成本文称为P颗粒的二十面体形式。提出了影响P颗粒形成和稳定性的因素，以及提供诊断和治疗诺如病毒感染个体以及创造用于预防诺如病毒感染的疫苗的方法。

5. 发明申请

WO2003101176A3 METHOD, COMPOSITION AND KIT FOR ANTIGENIC BINDING OF NORWALK-LIKE VIRUSES 审中-公开
公开(公告)号：WO2003101176A3
公开(公告)日：2003-12-11
申请号：PCT/US2003/017247
申请日：2003-06-02
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER , LE PENDU, Jacques , JIANG, Xi
发明人： LE PENDU, Jacques , JIANG, Xi
IPC分类号： C12Q1/70
摘要： A method for detecting a Norwalk-Like Virus (NLV) in a biological sample, comprising the steps of: obtaining a biological sample suspected of containing a NLV; contacting the biological sample with at least one human histo-blood group antigen to allow formation of a complex of the NLV with the antigen; and detecting the antigen NLV complex. The antigen-NLV complex can be detected by contacting the NLV-antigen complex with a NLV antibody that binds at an epitope of the NLV, and detecting the NLV antibody. The invention also includes a method for identifying compounds, and the compounds, that can inhibit the binding between a Norwalk-Like Virus (NLV) and a histo-blood group antigen. The method includes the steps of contacting the NLV target with a compound; subsequently contacting the NLV with a standard compound that is known to be bound at a determinant binding site of the NLV; and determining whether the binding of the standard compound is decreased in the presence of the test compound, the decrease in binding being an indication that the test compound inhibits the binding activity of the NLV with the standard compound. In preferred embodiments, the standard compound is a histo-blood group antigen.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式